DAPT in DES-PCI (ACS): Clopidogrel even better than Ticagrelor?

被引：0
|
作者：
Franke, Katharina
机构：
来源：
AKTUELLE KARDIOLOGIE | 2018年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 25 条
  • [1] Ticagrelor (Brilinta) - Better Than Clopidogrel (Plavix)?
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1372): : 69 - 70
  • [2] Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes
    Bach, Richard G.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 166 (04) : JC22 - JC22
  • [3] Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: back to square one for DAPT?
    Sinnaeve, Peter R.
    Van de Werf, Frans
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 (41) : 3079 - 3081
  • [4] Ticagrelor-Mono- or NOAK/P2Y12 according to DES-PCI: Less is more
    Franke, Katharina
    [J]. AKTUELLE KARDIOLOGIE, 2020, 9 (01) : 14 - +
  • [5] DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan
    Yueh-Chung Chen
    Feng-Yen Lin
    Yi-Wen Lin
    Shu-Meng Cheng
    Rong-Ho Lin
    Chun-Ling Chuang
    Jehn-Shing Sheu
    Shan-Min Chen
    Chao-Chien Chang
    Chien-Sung Tsai
    [J]. American Journal of Cardiovascular Drugs, 2019, 19 : 75 - 86
  • [6] DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan
    Chen, Yueh-Chung
    Lin, Feng-Yen
    Lin, Yi-Wen
    Cheng, Shu-Meng
    Lin, Rong-Ho
    Chuang, Chun-Ling
    Sheu, Jehn-Shing
    Chen, Shan-Min
    Chang, Chao-Chien
    Tsai, Chien-Sung
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (01) : 75 - 86
  • [7] USE OF CLOPIDOGREL, PRASUGREL AND TICAGRELOR IN PATIENTS WITH NSTE-ACS UNDERGOING PCI IN CLINICAL PRACTICE: RESULTS OF THE ALKK-PCI REGISTRY
    Zeymer, Uwe
    Hochadel, Matthias
    Elsaesser, Albrecht
    Andresen, Dietrich
    Zahn, Ralf
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A113 - A113
  • [8] Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Al-Abdouh, Ahmad
    Barbarawi, Mahmoud
    Abusnina, Waiel
    Amr, Mahmoud
    Zhao, Di
    Savji, Nazir
    Hasan, Rani K.
    Michos, Erin D.
    [J]. CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2020, 21 (12) : 1613 - 1618
  • [9] Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
    Mattia Peyracchia
    Andrea Saglietto
    Carloalberto Biolè
    Sergio Raposeiras-Roubin
    Emad Abu-Assi
    Tim Kinnaird
    Albert Ariza-Solé
    Christoph Liebetrau
    Sergio Manzano-Fernández
    Giacomo Boccuzzi
    Jose Paulo Simao Henriques
    Stephen B. Wilton
    Lazar Velicki
    Ioanna Xanthopoulou
    Luis Correia
    Andrea Rognoni
    Ugo Fabrizio
    Iván Nuñez-Gil
    Andrea Montabone
    Salma Taha
    Toshiharu Fujii
    Alessandro Durante
    Sebastiano Gili
    Giulia Magnani
    Michele Autelli
    Alberto Grosso
    Tetsuma Kawaji
    Pedro Flores Blanco
    Alberto Garay
    Giorgio Quadri
    Berenice Caneiro Queija
    Zenon Huczek
    Rafael Cobas Paz
    José Ramón González-Juanatey
    María Cespón Fernández
    Shao-Ping Nie
    Maurizio D’Amico
    Isabel Muñoz Pousa
    Masa-aki Kawashiri
    Diego Gallo
    Umberto Morbiducci
    Alberto Dominguez-Rodriguez
    Angel Lopez-Cuenca
    Angel Cequier
    Dimitrios Alexopoulos
    Andrés Iñiguez-Romo
    Walter Grossomarra
    Tullio Usmiani
    Mauro Rinaldi
    Fabrizio D’Ascenzo
    [J]. American Journal of Cardiovascular Drugs, 2020, 20 : 259 - 269
  • [10] Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries
    Peyracchia, Mattia
    Saglietto, Andrea
    Biole, Carloalberto
    Raposeiras-Roubin, Sergio
    Abu-Assi, Emad
    Kinnaird, Tim
    Ariza-Sole, Albert
    Liebetrau, Christoph
    Manzano-Fernandez, Sergio
    Boccuzzi, Giacomo
    Henriques, Jose Paulo Simao
    Wilton, Stephen B.
    Velicki, Lazar
    Xanthopoulou, Loanna
    Correia, Luis
    Rognoni, Andrea
    Fabrizio, Ugo
    Nunez-Gil, Ivan
    Montabone, Andrea
    Taha, Salma
    Fujii, Toshiharu
    Durante, Alessandro
    Gili, Sebastiano
    Magnani, Giulia
    Autelli, Michele
    Grosso, Alberto
    Kawaji, Tetsuma
    Flores Blanco, Pedro
    Garay, Alberto
    Quadri, Giorgio
    Caneiro Queija, Berenice
    Huczek, Zenon
    Cobas Paz, Rafael
    Ramon Gonzalez-Juanatey, Jose
    Cespon Fernandez, Maria
    Nie, Shao-Ping
    D'Amico, Maurizio
    Munoz Pousa, Isabel
    Kawashiri, Masa-aki
    Gallo, Diego
    Morbiducci, Umberto
    Dominguez-Rodriguez, Alberto
    Lopez-Cuenca, Angel
    Cequier, Angel
    Alexopoulos, Dimitrios
    Iniguez-Romo, Andres
    Grossomarra, Walter
    Usmiani, Tullio
    Rinaldi, Mauro
    D'Ascenzo, Fabrizio
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (03) : 259 - 269
123